Masthead

360 Series Panel Collection

Masthead

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

Ideal for studying solid tumors, the 360 Series Panel Collection can be used to better understand the biology behind therapeutic response, therapeutic mechanism of action, immune evasion, and the interplay between the tumor and microenvironment. These panels serve as powerful tools for developing novel signatures that correlate with response and/or survival.

  • 1,588 unique genes included across all panels
  • PAM50, Claudin-Low, & Triple Negative Breast Cancer (TNBC) gene signatures included in the Breast Cancer 360 Panel
  • Data Analysis Service for the IO 360 and Breast Cancer 360 Panels provides interactive and customizable reports with signatures scores
  • Pairs with GeoMx® Cancer Transcriptome Atlas for comparative spatial RNA profiling

How It Works

Selecting your panel
Tumor Inflammation Signature
Product Bulletins
Selecting your panel

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Tumor Inflammation Signature

The Tumor Inflammation Signature1 includes 18 functional genes often associated with the response to PD-1/PD-L1 checkpoint inhibitors. It is embedded into all of the 360 series panels: The PanCancer IO 360 Panel, the Breast Cancer 360 Panel, and the Tumor Signaling 360 Panel.

  • Includes four areas of immune biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.
  • Highlights the complex biology of the host immune microenvironment.

View publication and video.

1. Ayers, Mark, et al. “IFN-y-related mRNA profile predicts clinical response to PD-1 blockade.” The Journal of Clinical Investigation 127.8 (2017).

Related Resources

See all resources
Blog The IO Revolution, Part 1 of 4: Opportunities and Challenges
Blog The IO Revolution, Part 1 of 4: Opportunities and Challenges
Blog The IO Revolution, Part 1 of 4: Opportunities and Challenges
Blog The IO Revolution, Part 1 of 4: Opportunities and Challenges
Blog The IO Revolution, Part 1 of 4: Opportunities and Challenges

Publications

View all publications

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.

Medulloblastoma (MB) is the most common primary malignant pediatric brain cancer. We recently identified novel roles for the MEK/MAPK pathway in regulating human Sonic Hedgehog (SHH) MB tumorigenesis.

Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma.

Immune checkpoint blockade (ICB) using anti-PD-1/PD-L1 and anti-CTLA-4 antibodies significantly enhances survival in metastatic melanoma patients and has recently been shown to prolong relapse-free survival in stage III and high-risk stage II melanoma patients ( Eggermont et al. , 2018; Luke et al.

Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature.

Background: Intraductal papillary mucinous neoplasms (IPMN) are the only radiographically identifiable precursor to pancreatic adenocarcinoma, yet little is known about how these lesions progress to cancer. Inflammation has been associated with dysplastic progression; however, the cause and composition of this inflammation remains poorly characterized.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us